Discovery Life Sciences™ (Discovery), a global leader in biospecimen, genomic sequencing, cell, and immunohistochemistry (IHC) services, announced today the acquisition of East West Biopharma, a leading human biospecimen contract research organization in Europe powered by the largest biocollection network in Ukraine. The addition of East West Biopharma builds on Discovery’s existing capability and creates Europe’s largest network of clinical collection sites that ethically obtain consented biospecimens from patients across multiple therapeutic areas to support the global medical research community.
Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”), a fully integrated contract research and manufacturing organization offering laboratory, CMC and clinical development services for the life science industry, announced Sunday that it has acquired 100% of the equity of Absorption Systems for up to US$137.5 million in cash. Absorption Systems is a leading scientific, non-clinical CRO that provides pharmaceutical, biotech, medical device companies and regulatory agencies with research and testing for small and large molecules, cell and gene therapies, ocular and medical device products. Absorption Systems is based in the USA with facilities and laboratories in Philadelphia, San Diego and Boston.
Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector, announced today that it has entered into a definitive agreement to sell its portfolio company, Synteract Inc. (“Synteract” or the “Company”), a leading contract research organization (CRO) that supports biotech and pharma companies across all phases of drug development, to Syneos Health, Inc. (“Syneos Health”) (NASDAQ: SYNH). Amulet acquired Synteract in May 2016 and recruited industry veteran Steve Powell, who joined the Company as CEO in 2017. The executive team organized the Company around centers of development in the high-growth therapeutic areas of oncology, dermatology, neuroscience, pediatrics and rare and orphan diseases, while also expanding the Company’s global delivery capacity across three continents.
MLM Medical Labs (“MLM”), a Great Point Partners portfolio company, announced Tuesday the acquisition of MD Biosciences, Inc., based in Oakdale, Minnesota. MD Biosciences is a global, industry-leading provider of preclinical, translational and clinical-phase contract research services for the development of pharmaceutical and diagnostic assets. With AAALAC-accredited, GLP-compliant and CLIA-certified facilities, MD Biosciences offers a wide range of validated and customizable models including inflammatory, autoimmunity, oncology, and metabolic diseases. MD Biosciences operates a full-service histopathology lab including digital image analysis. MD Biosciences Bioproducts and MD Biosciences Israel, which focuses on preclinical and translational research in neurology, are not part of this transaction.
St. Cloud Capital is pleased to announce an investment in Charlotte, North Carolina-based Catawba Research (“Catawba” or the “Company”). St. Cloud has partnered with a financial investment firm focused on control investments in the life sciences and industrial sectors to support Catawba’s next phase of growth. It is an investment out of St. Cloud’s third fund, which has committed capital of $250 million. Catawba is a vertically integrated contract research organization (“CRO”) providing clinical management services to pharmaceutical and biotechnology companies globally. The Company focuses on Phase II – IV trials across the dermatology, women’s health, ophthalmology and gastroenterology therapeutic areas.
Blackstone Group Inc., one of the world’s largest investment firms, is nearing a deal to buy Precision Medicine Group for about $2.3 billion, according to people familiar with the matter. The firm is set to buy a majority stake in the group from existing backers Berkshire Partners and TPG, said the people, who asked not to be identified because they weren’t authorized to speak publicly. No deal has been finalized and Blackstone may choose not to go ahead with the transaction.
CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization (CRO) announces the acquisition of Clinart, a full-service CRO with nearly 20 years of experience and strong local expertise in the Middle East and Northern Africa (MENA) region. Clinart provides an extensive array of services, from early to late-stage research as well as product support in accordance with global and regional requirements. Additionally, the Clinart footprint augments CTI’s current reach in the MENA region, with associates in Egypt, Morocco, Tunisia, Lebanon, Saudi Arabia, Kuwait, Jordan, Oman, and United Arab Emirates, enabling CTI to better serve its customers and their global programs.
Sier Capital Partners is excited to announce it is supporting the management team of Integrated Laboratory Systems (ILS) in an acquisition of the company. ILS is a Contract Research Organization providing research and pre-clinical toxicology testing services to the Federal government, as well as the biopharmaceutical, chemical, agrochemical, food additive, and consumer product industries. ILS conducts investigative in vivo and in vitro toxicology, genetic toxicology, computational toxicology, histology, pathology, molecular biology, and information science services tailored to meet clients’ needs.
CATO SMS announced today that it has acquired Wilmington, NC-based Array Biostatistics (Array) to expand its offering of specialized clinical research solutions. The company plans to invest in growing Array and its highly regarded biostatistical capabilities. Both Array and CATO SMS offer highly specialized services that expedite and support drug development for small and emerging biopharmaceutical companies. By acquiring Array, CATO SMS adds expertise and scale to its full-service biostatistical consulting, analysis and programming capabilities.
Aldevron, a leading manufacturer of plasmid DNA, proteins and mRNA, today announced the sale of its Germany based antibody discovery business. Brian Walters, current president of the business unit and longtime employee of Aldevron, led a group of investors to purchase the business for an undisclosed amount. The transaction is effective immediately. The new business will operate under the name GENOVAC, the original name of the German company purchased by Aldevron in 2004.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.